1 / 19

Attention-deficit/hyperactivity disorder

Attention-deficit/hyperactivity disorder. Puja Patel PGY5 Pediatric Neurology Nov 6, 2013. Epidemiology. Overall prevalence 2-18% School age children 8-10%  most common neurobehavioral disorder of childhood More common in boys than girls Male to female ratios:

jolene-joseph
Download Presentation

Attention-deficit/hyperactivity disorder

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Attention-deficit/hyperactivity disorder Puja Patel PGY5 Pediatric Neurology Nov 6, 2013

  2. Epidemiology • Overall prevalence 2-18% • School age children 8-10%most common neurobehavioral disorder of childhood • More common in boys than girls • Male to female ratios: • 4:1 for predominantly hyperactive type • 2:1 for predominantly inattentive type

  3. Clinical Features 2 categories of core symptoms: • Hyperactive and impulsive behaviors occur together • Inability to sit still or inhibit behavior • Observed by age 4, peaks age 7-8, then hyperactive symptoms decline but impulsive symptoms persist • Inattention • Reduced ability to focus attention, reduced speed of cognitive processing and responding • Apparent at 8-9 years old, usually lifelong

  4. Diagnostic Criteria DSM-5 • Age <17 years: ≥6 symptoms in 1 or both categories • Age ≥17 years, ≥5 symptoms of in 1 or both categories • Present > 1 setting • Persist > 6mo • Present before age 12 • Inconsistent with developmental level child • Impair functioning • Exclude psychiatric disorders

  5. DSM-4 vs DSM-5 • New overall diagnostic category • Neurodevelopmental disorders(DSM-5) vsDisorders usually first diagnosed in infancy, childhood and adolescence (DSM-4) • ADHD across lifespan • Not only a disorder of childhood • Adding new examples to apply criteria across lifespan • Lower age cutoff for diagnosis in adults • Age of onset changed from 7 to 12 • Removal of PDD/ASD from exclusion criteria • Allows for diagnosis of ADHD with comorbid PDD/ASD

  6. Changes from subtypes to presentations: DSM-4 vs DSM-5 DSM-4 DSM-5 • Combined subtype • Inattention + hyperactive-impulsivity • Predominantly inattentive type • Predominantly hyperactive-impulsive type • Combined presentation • Predominantly inattentive • 6 inattentive and 3-5 hyperactive/impulsive symptoms • Inattentive (restrictive) • 6 inattentive and no more than 2 hyperactive/impulsive symptoms • Predominantly hyperactive/impulsive

  7. Prevalence distribution of DSM-4 subtypes

  8. Etiologies Genetic factors account for ~80% of etiology • Twin studies demonstrate concordance as high as 92% in monozygotic twins and 33% in dizygotic twins • 5-6x higher risk of first degree relatives affected • Genes that may play a role: • DA and serotonin-Rs and transporters • DA beta-hyroxylase • Glutamate-R

  9. Etiologies Mixed reviews on environmental factors: • Maternal factors • Smoking, prenatal alcohol, lead, viral infections • Perinatal/early life risk factors • Premature infants with BW<1500gm • Striatum and cingulate-cortical loop vulnerable to ischemia induced release of glutamate • Post-natal risk factors • Cerebral trauma/infections, thyroid dysfunction, toxins, nutritional deficiencies • Genetic factor likely basic cause;environmental factor probably secondary, acting as a trigger

  10. Comorbid disorders Prevalence of comorbid disorders for children with ADHD vs those without • Primary vs secondary • ADHD subtype specific comorbidities Larson et al, 2007

  11. Evaluation • Keep in mind diagnostic criteria for ADHD • Evaluate medical/neurologic/developmental disorders • Hearing/visual impairment, genetic/metabolic, sleep d/o, seizures, med effects, learning disabilities, language d/o • FHx similar behaviors • Evaluate for emotional/social stressors • Screen for psychiatric conditions • Substance abuse in adolescents

  12. Evaluation • Behavior rating scales to be completed > 2 informants • ADHD specific (narrow-band): focus directly on core symptoms • Sensitivity and specificity>90% • Conners and the ADHD Rating Scale IV for preschoolers • Vanderbilt for children ≥4 years • Broadband scales: Assess variety of behavioral symptoms • Less sensitive and specific • Can help identify coexisting conditions • Educational evaluation mandated by schools in US • Core symptoms in classroom • Neuropsych testing (IQ and academic) to eval learning d/o

  13. Treatment • Preschool children (4-5yo) • Behavior therapy administered by parent or teacher • Addition of medication (stimulant) if fails behavioral therapy • School age children (6-11yo) and adolescents (12-18yo) • Medication + behavioral therapy • Treat coexisting conditions concurrently with ADHD

  14. Behavior therapy • Modifications in physical and social environment using rewards and nonpunitiveconsequences • Positive reinforcement, time-out, token economy • Small reachable goals • Keep organized: maintaining daily schedule, charts/checklists • Keep on task: minimum distractions, limiting choices • School based interventions • Qualifications for special ed/IEP/accommodations under section 504 • Tutoring/resource room support • Classroom modifications • Extended time to complete tasks

  15. Pharmacologic Treatments Stimulants first line • Methylphenidate (Ritalin), dexmethylphenidate (focalin), amphetamine (adderall) • NE and DA reuptake inhibitor/releasing agent • Advantages: rapid onset of action, safe, long and short-acting forms approved in children<6 • SEs: appetite suppression, retard growth trajectory, insomnia, mood lability, rebound, tics, psychosis, abuse potential, sudden cardiac death (rare)

  16. Pharmacologic Treatments Non-stimulants • Atomoxetine (straterra) • NE reuptake inhibitor • Adv: no abuse potential • Disadv: less effective than stimulants, decrease dose if use with P450 inhibitors • SEs: somnolence, GI symptoms, decreased appetite, SI (rare), hepatitis (rare) • Alpha-2 adrenergic agonists (not FDA approved) • Guanfacine(tenex), clonidine (catapres) • Adv: no abuse potential, helpful if coexisting sleep or tic disorders • Disadv: less effective than stimulants • SEs: somnolence, dry mouth, hypotension, orthostasis

  17. Treatment considerations • Monitor treatment response • Drug holidays not routinely recommended • Consider if aberrant growth trajectory, excessive SEs • Stopping medications • Consider if stable symptoms • Time appropriately • Stimulant medications and atomoxetine do not need taper • Taper alpha-2-adrenergic agonists

  18. Prognosis 30-60% continue to manifest appreciable symptoms into adult life • Impaired academic functioning • especially for inattentive or combined types • Some data suggests decreased rate of employment, lower job status and poor job performance • Increased risk for incurring intentional or unintentional injury • Increased risk for antisocial personality disorder in adulthood

  19. References • Dalsgaard S. Attention-deficit/hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 2013 Feb;22 Suppl1:S43-8 • DaughtonJM, Kratochvil CJ. Review of ADHD pharmocotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009;48(3):240-8 • Klein RG et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 2012;69(12):1295-303 • Larson K et al. Patterns of Comorbidity, Functioning, and Service Use for US children with ADHD, 2007. Pediatrics 2011; 127(3):462-70 • MillichapJG. Etiological Classification of Attention-Deficit/Hyperactivity Disorder. Pediatrics 2008;121(2): 358-65 • WolraichM et al. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatmentof Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 2011 Nov;128(5):1007-22 • UpToDate, “ADHD in children and adolescents,” 2013 • Clinical Features and Evaluation; Epidemiology and Pathogenesis; Overview of treatment and Prognosis; Treatment with Medications

More Related